Breaking News, Collaborations & Alliances, Trials & Filings

Trials & Filings in Brief: Dec. 18, 2013

Andromeda Biotech, Banner Pharmacaps, Bayer Healthcare, Genmab, Gilead, GlaxoSmithKline, Ipsen, Lonza, Mylan, Octapharma, Omeros, Regeneron, Versartis

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

Phase II
Octapharma begins enrolling MS patients . . . read more

Phase III
Andromeda begins dosing in diabetes extension trial . . . read more

Gilead posts SOF/LDV SVR12 results . . . read more

Filings
Eylea sBLA accepted by FDA . . . read more

GSK, Genmab sBLA for Arzerra in CLL gets priority review . . . read more

Ipsen files to resupply Increlex in EU . . . read more

Mylan, Banner reach Targretin settlement with Eisai, Valeant . . . read more

Omeros receives Orphan Designation for TMA treatment . . . read more

Versartis GHD treatment gets Orphan Designation . . . read more

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters